Belgija - angleščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - fingolimod hydrochloride 0,56 mg - eq. fingolimod 0,5 mg - capsule, hard - fingolimod

Belgija - angleščina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

reddy holding gmbh - fingolimod hydrochloride 0,56 mg - eq. fingolimod 0,5 mg - capsule, hard - fingolimod

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; mannitol - filosir is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: gelatin; titanium dioxide; mannitol; magnesium stearate; iron oxide yellow - fynefta is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Panama - angleščina - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios stein, s.a. - fingolimod (clorhidrato) - fingolimod (clorhidrato)....0,50 mg

Panama - angleščina - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

accord healthcare, s.l.u. - fingolimod (clorhidrato) - fingolimod (clorhidrato)....0,50 mg

Panama - angleščina - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

synthon chile ltda. - fingolimod (clorhidrato) - fingolimod (clorhidrato)....0.5 mg

Združene države Amerike - angleščina - NLM (National Library of Medicine)

cycle pharmaceuticals ltd - fingolimod lauryl sulfate (unii: j3hzq9be2s) (fingolimod - unii:3qn8byn5qf) - tascenso odt is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. tascenso odt is contraindicated in patients who have: - in the last 6 months experienced myocardial infarction, unstable angina, stroke, tia, decompensated heart failure requiring hospitalization or class iii/iv heart failure - a history or presence of mobitz type ii second-degree or third-degree av block or sick sinus syndrome, unless patient has a functioning pacemaker [see warnings and precautions (5.1)] - a baseline qtc interval ≥ 500 msec - cardiac arrhythmias requiring anti-arrhythmic treatment with class ia or class iii anti-arrhythmic drugs - had a hypersensitivity reaction to fingolimod or any of the excipients in tascenso odt. observed reactions include rash, urticaria, and angioedema [see warnings and precautions (5.14)]. - concomitant use with other products c

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fingolimod hydrochloride, quantity: 0.28 mg (equivalent: fingolimod, qty 0.25 mg) - capsule, hard - excipient ingredients: mannitol; hyprolose; hydroxypropylbetadex; magnesium stearate; shellac; iron oxide black; propylene glycol; gelatin; strong ammonia solution; titanium dioxide; iron oxide yellow - filosir is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fingolimod hydrochloride, quantity: 0.28 mg (equivalent: fingolimod, qty 0.25 mg) - capsule, hard - excipient ingredients: mannitol; hyprolose; hydroxypropylbetadex; magnesium stearate; shellac; iron oxide black; propylene glycol; gelatin; strong ammonia solution; titanium dioxide; iron oxide yellow - fynefta is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.